Fresh analysis suggests that patients who come off blockbuster slimming jabs like semaglutide or tirzepatide can put back on reduced body mass much more quickly than those who halt conventional diet and exercise plans.
Findings released in a major health publication points out that while obese people often shed about a fifth of their body weight while undergoing treatment, the weight comes back at an estimated rate of 0.8 kg per month once they quit.
"People purchasing such drugs should be aware of the potential of quick rebound weight gain when the medication ends," stated lead investigator Dr. Susan Jebb.
This pace of regain implies a return to starting weight within about a year and a half.
Comparing Approaches
The analysis, which looked at 37 of studies involving thousands of participants, contrasted the results of the injectable medications with conventional dieting.
Scientists note that individuals who lose weight through dieting typically have a slower weight regain—around 100 grams monthly—after stopping.
Explaining the Quick Rebound
Nutrition scientists suggest the way of the jabs is key to understanding the accelerated rebound.
GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which helps regulate hunger.
"Sustained high doses of the hormone concentrations several times higher than the body's typical production may cause the body to generate a reduced amount of its own natural GLP-1, and may also lessen responsiveness to its effects," noted Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this hormone supplement leads to hunger is uncontrolled, making excessive eating far more likely."
An Ongoing Issue?
Health authorities suggest the jabs for people with weight-linked health risks, accompanied by prescribed diet and exercise modifications.
Many experts contend that, due to the high risk of weight regain, the treatment should be considered life-long.
This view is reinforced by drug manufacturers, who note that the findings "underscore the persistent character of excess weight," akin to managing conditions like diabetes.
User Accounts
People who have stopped the jabs report a powerful resurgence of cravings.
"I experienced something flipping and you're instantly extremely hungry," recalled a patient.
This difficulty is exacerbated if individuals have not established sustainable dietary or behavioural modifications during treatment.
Growing Adoption
Survey data show that a significant number of people in the UK have used these injections in the last 12 months, with interest remaining high.
- Use is higher among females than males.
- The 40s and 50s age group shows the highest usage rates.
- Many access the drugs through private healthcare rather than the NHS.
Finally, clinicians caution that while GLP-1 drugs are powerful agents for weight loss, they are not a permanent cure and long-term success likely depends on integrated lifestyle support.
